Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, affecting an estimated 2 million people worldwide, and is the second cause of neurological disability in young adults after traumatic brain injuries. Although the aetiology remains unknown, several lines of evidence support autoimmunity as playing a major role in disease development. MS incidence has significantly increased during the second half of the twentieth century. This has been attributed to changes in certain environmental factors, including a significant decline in exposure to infections, due to better public health practices. Epidemiological studies suggest autoimmune diseases, such as MS, are less frequent in individuals infected by certain kinds of parasites, particularly those called helminths. This observation has been tested in different autoimmune disease animal models in which mice colonized with helminths show protection from disease. Downmodulation of inflammatory responses resulting from helminth infection has sparked interest in exploring the potential clinical efficacy of establishing controlled infections in patients suffering from autoimmune diseases, using live parasitic worms, in an attempt to decrease disease severity. To date, clinical trials using helminth therapy in MS have been safety-oriented and small in size, seeking to reproduce and confirm epidemiological and experimental data. Clearly, longer studies, monitoring safety and objective outcome measures are necessary to assess this novel therapeutic strategy. Alternatively, identification of helminth-derived immunomodulatory molecules mimicking the protective effects of parasite infections might also help combat autoimmune diseases without undesired side effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
McFarland H, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919
Marrie RA (2004) Environmental risk factors in multiple sclerosis. Lancet Neurol 3:709–718
Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL (2008) The genetics of multiple sclerosis: SNP to pathways to pathogenesis. Nat Rev Gen 9:516–526
Gourraud PA, Harbo HF, Hauser SL, Baranzini SE (2012) The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 248:87–103
Rosati G (2011) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22:117–139
Alter M, Kahana E, Lowenson R (1978) Migration and risk of multiple sclerosis. Neurology 28:1089–1093
Riise T, Groonning M, Klauber MR, Barret-Connor E, Nyland H, Albreksten G (1991) Clustering of residence of multiple sclerosis patients at age 13 to 20 in Hordaland, Norway. Am J Epidemiol 133:932–939
Pugliatti M, Riise T, Sotgiu MA et al (2006) Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in Sardinian population. Am J Epidemiol 164:326–333
Melcon MO, Correale J, Melcon CM (2014) Is it time for a new global classification of multiple sclerosis? J Neurol Sci 344:171–181
Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61:504–513
Ascherio A (2013) Environmental factors in multiple sclerosis. Expert Rev Neurother 13(12 Suppl):3–9
DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC (2013) Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 39:458–484
Koch MW, Metz LM, Agrawal SM, Yong VW (2013) Environmental factors and their regulation of immunity in multiple sclerosis. J Neurol Sci 324:10–16
Christen U, von Herrath MG (2005) Infections and autoimmunity-good or bad? J Immunol 174:7481–7486
Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659
Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920
Leibowitz U, Atanovsky A, Medalie JM, Smith HA, Halpern L, Alter M (1966) Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and the level of sanitation. J Neurol Neurosurg Psychiatry 29:60–68
Rook GAW (2009) The changing microbial environment, Darwinian medicine and the hygiene hypothesis. In: Rook GAW (ed) The hygiene hypothesis and Darwinian medicine. Birkhäuser, Basel, pp 1–27
Fleming JO, Cook TD (2006) Multiple sclerosis and the hygiene hypothesis. Neurology 67:2085–2086
van den Bigeelar AH, Rodrigues LC, van Ree R et al (2004) Long-term treatment of intestinal helminthes increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis 189:892–900
Correale J, Farez M (2011) The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 233:6–11
La Flamme AC, Ruddenklau K, Bäckström BT (2003) Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun 71:4996–5004
Zaccone P, Fehervari Z, Jones FM et al (2003) Schistosoma mansoni modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol 33:1439–1449
Osada Y, Shimizu S, Kumagai T, Yamada S, Kanazawa T (2009) Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of por-inflammatory mediators. Int J Parasitol 39:457–464
Elliot DE, Li J, Blum A, Metwali A, Qadir K, Urban JF, Weinstrock JV (2003) Exposure to schistosome eggs portects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 284:G385–G391
Hasseldam H, Hansen CS, Johansen FF (2013) Immunomodulatory effects of helminths and protozoa in multiple sclerosis and experimental autoimmune encephalomyelitis. Parasite Immunol 35:103–108
Hunter MM, Wang A, Hirota CL, McKay DM (2007) Helminth infection enhances disease in a murine TH2 model of colitis. Gastroenterology 132:1320–1330
McSorley HJ, Maizels RM (2012) Helminth Infections and host immune regulation. Clin Microbiol Rev 25:585–608
Maizels RM, Hewitson JP, Smith KA (2012) Susceptibility and immunity to helminth parasites. Curr Opin Immunol 24:459–466
Maizels RM, Yazdanbakhsh M (2008) T-cell regulation in helminth parasite infections:implications for inflammatory diseases. Chem Immunol Allergy 94:112–123
Correale J, Farez M (2007) Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 61:97–108
Correale J, Farez M, Razzitte G (2008) Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 64:187–199
Bager P, Arnved J, Rønborg S et al (2010) Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 125:123–130
Summers RW, Elliot DE, Urban JF Jr, Thompson RA, Weinstrock JV (2005) Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128:825–832
Summers RW, Elliot DE, Urban JF Jr, Thompson R, Weinstrock JV (2005) Trichuris suis therapy in Crohn’s disease. Gut 54:87–90
Graepel R, Leung G, Wang A et al (2013) Murine autoimmune arthritis is exaggerated by infection with the rat tapeworm, Hymenolepis diminuta. Int J Parasitol 43:593–601
Fleming JO (2013) Helminth therapy in multiple sclerosis. Int J Parasitol 43:259–274
Tilp C, Kapur V, Loging W, Erb KJ (2013) Prerequisites for the pharmaceutical industry to develop and commercialise helminthes and helminth-derived product therapy. Int J Parasitol 43:319–325
Fleming JO, Isaak A, Lee JE, Luzzio CC et al (2011) Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 17:743–754
Voldsgaard A, Bager P, Kapel C et al (2012) Trichuris suis ova therapy for relapsing multiple sclerosis—a safety study. Neurology 78:S30.005
Benzel F, Erdur H, Kholer S, Frentsch M et al (2012) Immune monitoring of trichuris suis egg therapy in multiple sclerosis patients. J Helminthol 86:339–347
Rosche B, Wernecke KD, Ohlaraun S, Dörr JM, Paul F (2013) Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIONS): study protocol for a randomized controlled trial. Trials 14:112
Elias D, Akuffo H, Pawlowski A, Haile M, Schön T, Britton S (2005) Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23:1326–1334
Cruz-Chan JV, Rosado-Vallado M, Dumonteil E (2010) Malaria vaccine efficacy: overcoming the helminth hurdle. Exp Rev Vaccines 9:707–711
Sabin EA, Araujo MI, Carvalho EM, Pearce EJ (1996) Impairment of tetanus toxoid-specific Th1-like immune responses in human infected with Schistosoma mansoni. J Infect Dis 173:269–272
Bassily S, Hyams N, El-Ghorab M, Mansour MM, El-Masry NA, Dunn MA (1987) Immunogenicity of hepatitis B vaccine in patients infected with Schistosoma mansoni. Am J Trop Med Hyg 36:549–553
Mortimer K, Brown A, Feary J et al (2006) Dose ranging study for trials of therapeutic infection with Necator americanus in humans. Am J Trop Med Hyg 75:914–920
Shin J, Gardiner GW, Deitel W, Kandel G (2004) Does whipworm increase the pathogenicity of Campylobacter jejuni? A clinical correlate of an experimental observation. Can J Gastroenterol 18:175–177
Mansfield LS, Gauthier DT, Abner SR, Jones KM, Wilder SR, Urban JF (2003) Enhancement of disease and pathology by synergy of Trichuris suis and Campylobacter jejuni in the colon of immunologically naive swine. Am J Trop Med Hyg 63:70–80
Wolff MJ, Braodhurst MJ, Loke P (2012) Helminthic therapy: improving mucosal barrier function. Trends Parasitol 28:187–194
Johnston MJG, MacDonald JA, McKay DM (2009) Parasitic helminthes: apharmacopeia of anti-inflammatory molecules. Parasitology 136:125–147
Danilowiz-Luebert E, O’Regan NL, Steinfelder S, Hartmann S (2011) Modulation of specific and allergy-related immune responses by helminths. J Biomed Biotechnol 2011:821578
Pineda MA, McGrath MA, Smith PC et al (2012) The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum 64:3168–3178
Imai S, Tezuka H, Fujita K (2001) A factor inducing IgE from a filarial parasite prevents insulin-dependent diabetes mellitus in nonobese diabetic mice. Biochem Biophys Res Commun 286:1051–1058
Kuijk LM, Klaver EJ, Kooij G (2012) Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol Immunol 51:210–218
Zhu B, Trikudanathan S, Zozulya AL et al (2012) Immune modulation by Lacto-N-fucopentose III in experimental autoimmune encephalomyelitis. Clin Immunol 142:351–361
Wammes LJ, Mpairwe H, Elliot AM, Yazdanbakhsh M (2014) Helminth therapy or elimination: epidemiological, immunological, and clinical considerations. Lancet Infect Dis 14:70771–70776
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Glossary
- Actinomycetes
-
Group of terrestrial or aquatic bacteria
- Allergy
-
Hypersensitivity disorder of the immune system. Symptoms include red eyes, itchiness, runny nose, eczema or asthma attacks
- Antibodies
-
Protein produced by the immune system to recognize or neutralize foreign molecules or micro-organisms
- Antigen
-
Any substance inducing a response of the immune system
- Autoimmune disease
-
Diseases arising as a result of an abnormal immune response by the body, directed against substances and tissues normally present in the body of the host
- Clinically isolated syndrome
-
First episode of a demyelinating disease. It is the step prior to MS development
- Commensal organisms
-
Organisms that obtain benefits from other organisms without producing any damage
- Cytokines
-
Broad and loose category of small proteins that are important in cell signalling. They are released by several cells but particularly by cells of the immune system and affect the behaviour of other cells, or even of the releasing cell itself
- Deworming
-
To give an antihelminthic drug to a person or animal to rid it of intestinal parasites
- Demyelinating disease
-
Disease produced by the loss of myelin
- Dendritic cell
-
Cells that recognize, process and present antigens to T cells, inducing their activation
- Experimental autoimmune encephalomyelitis (EAE)
-
Animal model that mimics essential clinical and pathological characteristics of MS. It can be induced in different species such as rabbit, guinea pigs, rats, mice or monkeys
- Gadolinium
-
Contrast medium used in magnetic resonance imaging studies to highlight abnormalities or disease process. In the brain, a gadolinium-positive lesion means the presence of inflammation
- Gut microbiota
-
Also known as gut flora is a complex group of micro-organism species inhabiting the digestive tract of animals and humans and the largest reservoir of commensal micro-organisms
- Helminths
-
Wormlike organisms living in and feeding on living hosts
- Incidence
-
Measure of the risk of developing some new condition within a given time period
- Interferon-γ
-
A type of cytokine that has most often a pro-inflammatory effect
- Interleukins
-
A group of cytokines produced by white blood cells
- Macrophage
-
Type of white blood cell that engulfs and digests cellular debris, foreign substances, microbes and cancer cells in a process called phagocytosis
- Magnetic resonance imaging (MRI)
-
Also known as nuclear magnetic resonance imaging (NMRI) is a medical imaging technique used in radiology to investigate the anatomy and physiology of the body. MRI scanners use strong magnetic fields and radio waves to form images of the body without exposure to ionizing radiation
- Multiple sclerosis
-
Inflammatory disease in which the insulating covers of nerve cells in the brain, spinal cord and optic nerve are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms
- Mycobacteria
-
Widespread bacteria, typically living in water and food sources. Some, however, including tuberculosis and the leprosy bacteria, appear to be obligate parasites and are not found as free-living members of the genus
- Natural killer cell
-
Type of cytotoxic lymphocytes that induce the death of tumour cells or virally infected cells
- Prevalence
-
Proportion of a population found to have a condition, typically a disease or a risk factor
- Saprophytes
-
Organisms obtaining nutrients from dead organic matter
- T helper cell (Th)
-
Type of T cell that helps the activity of other immune cells by releasing T cell cytokines. These cells help, suppress or regulate immune responses
- Transforming growth factor-β
-
Is a cytokine that controls proliferation, cellular differentiation and other functions in most cells
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Correale, J. (2016). Helminth Immunoregulation and Multiple Sclerosis Treatment. In: Alvergne, A., Jenkinson, C., Faurie, C. (eds) Evolutionary Thinking in Medicine. Advances in the Evolutionary Analysis of Human Behaviour. Springer, Cham. https://doi.org/10.1007/978-3-319-29716-3_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-29716-3_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29714-9
Online ISBN: 978-3-319-29716-3
eBook Packages: MedicineMedicine (R0)